eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
5.25
-0.02 (-0.38%)
Oct 9, 2026, 4:00 PM EDT - Market closed
eXoZymes Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
48.73M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.07K | 41.47K | 145.01% |
| Dec 31, 2022 | 28.60K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 34.59M |
| Celularity | 18.97M |
| Apollomics | 8.84M |
| ImageneBio | 800.00K |
| CervoMed | 331.30K |
| Serina Therapeutics | 130.00K |
| INmune Bio | 50.00K |
EXOZ News
- 7 days ago - Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity" - TheNewswire
- 11 days ago - eXoZymes Proxy statement: Proxy filing - Filings
- 11 days ago - eXoZymes Proxy statement: Proxy filing - Filings
- 4 weeks ago - eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT - Accesswire
- 6 weeks ago - eXoZymes Inc trading resumes - TheFly
- 6 weeks ago - eXoZymes Inc trading halted, volatility trading pause - TheFly
- 7 weeks ago - eXoZymes Earnings Call Transcript: Q2 2026 - Transcripts
- 7 weeks ago - eXoZymes Quarterly report: Q2 2026 - Filings